|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Looking to the future: biomarkers in themanagement of pancreatic adenocarcinoma 显示文摘 | Spratlin J L Mulder K E | 2011 | International journalof molecular sciences2011，12，9： | 1 |
| 2 | Ramucirumab(IMC-1121B):a novel attack on angiogenesis显示文摘 | Spratlin J Mulder K Mackey J | 2010 | Future Oncol2010，6，7： | 1 |
| 3 | Clinical applications ofmetabolomics in oncology: a review显示文摘 | Spratlin JL Serkova NJ Eckhardt SG | 2009 | Clin Cancer Res2009，15，2： | 1 |
| 4 | The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenucarcinoma 显示文摘 | Spratlin J Sangha R Darry Glubrecht D etal | 2004 | Clin Cancer Res2004，10，20： | 1 |
| 5 | Pharmacokinetics of paclitaxel metabolism显示文摘 | Spratlin J Sawyer MB | 2007 | Crit Rev Oncol/Hematol2007，61，3： | 1 |
| 6 | Pharmacogenetics of paclitaxel metabolism 显示文摘 | Spratlin J Sawyer MB | 2007 | Crit Rev Oncol Hematol2007，61，3： | 1 |
| 7 | Looking to the future:biomarkers in themanagement of pancreatic adenocarcinoma显示文摘 | Spratlin J L Mulder K E | 2011 | Int J Mol Sci2011，12，9： | 1 |
| 8 | The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma显示文摘 | Spratlin J Sangha R Glubrecht D | 2004 | Clin Cancer Res2004，10，20： | 1 |
| 9 | Community compliance with carcinoembryonic antigen: follow-up of patients with colorectal cancer 显示文摘 | Spratlin JL Hui D Hanson J | 2008 | Clin Colorectal Cancer2008，7，3： | 1 |
| 10 | Pharmacogenetics of paclitaxelmetabolism显示文摘 | Spratlin J Sawyer MB | 2007 | Crit Rev Oncol Hematol2007，61，3： | 1 |
| 11 | Beneficial effects of supplemental buffer and substrate on energy metabolism during small bowel storage显示文摘 | Salehi P Spratlin J Chong TF | 2004 | Cryobiology2004，48，3： | 1 |
| 12 | The absence of human equilibrative nucleoside transporterl is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma显示文摘 | Spratlin J Sangha R Glubrecht D | 2004 | Clin Cancer Res2004，10，20： | 1 |
| 13 | Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2显示文摘 | Spratlin JL Cohen RB Eadens M | 2010 | J Clin Oncol2010，28，5： | 1 |
| 14 | Pharmacogenetics of paclitaxel metabolism显示文摘 | SPRATLIN J SAWYER M B | 2007 | Crit Rev Oncol/He- matol2007，61，： | 1 |
| 15 | Clinical applications of metabolomics in oncology: a review显示文摘 | Spratlin JL Serkova N J Eckhardt SG | 2009 | Clin Cancer Res2009，15，2： | 1 |
| 16 | The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma显示文摘 | SPRATLIN J SANGHA R GLUBRECHT D | 2004 | Clin Cancer Res2004，10，20： | 1 |
| 17 | Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer:A prospective pilot study显示文摘BACKGROUND Despite optimal neoadjuvant chemotherapy only 40%of gastric cancer tumours achieve complete or partial treatment response.In the absence of treatment response,neoadjuvant chemotherapy in gastric cancer contributes to adverse events without additional survival benefit compared to adjuvant treatment or surgery alone.Additional strategies and methods are required to optimize the allocation of existing treatment regimens such as FLOT chemotherapy(5-Fluorouracil,Leucovorin,Oxaliplatin and Docetaxel).Predictive biomarkers detected using immunohistochemistry(IHC)methods may provide useful data regarding treatment response.AIM To investigate the utility of CD4,CD8,Galectin-3 and E-cadherin in predicting neoadjuvant FLOT chemotherapy tumour response in gastric adenocarcinoma.METHODS Forty-three adult patients with gastric adenocarcinoma,of which 18 underwent neoadjuvant chemotherapy,were included in a prospective clinical cohort.Endoscopic biopsies were obtained from gastric cancer and normal adjacent gastric mucosa.Differences in expression of Galectin-3,Ecadherin,CD4^(+)and CD8^(+)molecules between tumours with and without treatment response to neoadjuvant chemotherapy were assessed with IHC.Treatment response was graded by clinical pathologists using the Tumour Regression Score according to the College of American Pathologists criteria.Treatment response was defined as complete or near complete tumour response,whereas partial or poor/no response was defined as incomplete.Digital IHC images were annotated and quantitatively assessed using QuPath 0.3.1.Biomarker expression between responsive and incomplete response tumours was assessed using a two-sided Wilcoxon test.Biomarker expression was also compared between normal and cancer tissue and between 15 paired tumour samples before and after chemotherapy.We performed a preliminary multivariate analysis and power analysis to guide future study.Statistical analyses were completed using R 4.1.2.RESULTS The ratio between CD4^(+)and CD8^(+)lymphocytes was significantly greater in treatment responsive tumours(Wilcoxon,P=0.03).In univariate models,CD4^(+)/CD8^(+)ratio was the only biomarker that significantly predicted favourable treatment response(Accuracy 86%,P<0.001).Using a glmnet multivariate model,high CD4^(+)/CD8^(+)ratio and low Galectin-3 expression were the most influential variables in predicting a favourable treatment response.Analyses of paired samples found that FLOT chemotherapy also results in increased expression of CD4^(+)and CD8^(+)tumour infiltrating lymphocytes(Paired Wilcoxon,P=0.002 and P=0.008,respectively).Our power analysis suggests future study requires at least 35 patients in each treatment response group for CD8 and Galectin-3 molecules,whereas 80 patients in each treatment response group are required to assess CD4 and E-cadherin biomarkers.CONCLUSION We demonstrate that an elevated CD4^(+)/CD8^(+)Ratio is a promising IHC-based biomarker to predict favourable treatment response to FLOT neoadjuvant chemotherapy in locally advanced gastric cancer. | Daniel Skubleny Andrea Lin Saurabh Garg Ross McLean Michael McCall Sunita Ghosh Jennifer L Spratlin Daniel Schiller Gina Rayat | 2023 | World Journal of Gastrointestinal Oncology2023，15，2： | 1 |
| 18 | NMR-based metaboiomics:translational application and treatment of cancer显示文摘 | Serkova NJ Spratlin JL Eckhardt SG | | 0，，06： | 1 |
| 19 | Community compliance with eareinoembryonie antigen: follow-up of patients with eoloreetal cancer 显示文摘 | Spratlin JL Hui D Hanson J | 2008 | Clin Coloreetal Cancer2008，7，2： | 1 |
| 20 | How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer显示文摘 | Kim C Mulder K Spratlin J | 2014 | Oncologist2014，19，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员